POLE is an inclusion eligibility criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SDHB is an inclusion eligibility criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SDHB status and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TFE3 is an inclusion eligibility criterion in 2 clinical trials for non-clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TFE3 status and non-clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].